PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Islatravir→

Islatravir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
865363-93-5
Molecular formula
C12H12FN5O3
Molecular weight
293.25 g/mol
Drug class
Antiretroviralnucleoside reverse transcriptase translocation inhibitor (NRTTI)
Mechanism of action
A deoxyadenosine nucleoside analogue converted intracellularly to islatravir-triphosphate. The active triphosphate inhibits HIV reverse transcriptase by blocking translocation after incorporation into viral DNA, producing immediate and delayed chain termination.
Indications / reported uses
  • Used as part of the fixed-dose doravirine/islatravir antiretroviral regimen for HIV-1 infection in adults under the applicable product label.

Sources: https://clinicalinfo.hiv.gov/drugs/islatravir/health-professional · https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11aaeb53-9848-433c-be7f-db8a5bc0b26f

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Islatravir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Islatravir Permitted Daily Exposure (PDE) report (the Islatravir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Islatravir Occupational Exposure Limit (OEL) report (the Islatravir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.